PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] is a chemically novel and highly potent dopamine (D2) receptor agonist without D1 activity. It had significant antiparkinsonism effects when used as open-label monotherapy in ten patients who were Hoehn and Yahr stage 2 or 3. The standard formulation of PHNO produced a 3- to 4-hour therapeutic effect in most patients; the response to the time-release formulation lasted up to 10 hours. Side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient.
D000328:Adult; D000368:Aged; D004298:Dopamine; D015259:Dopamine Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D015259:Dopamine Agents; D010078:Oxazines; C042631:naxagolide; D004298:Dopamine